Table 2.

Biochemical and Immunophenotypical Characterization of Samples From Imatinib-Treated and Untreated Patients.

	Clinical Response*	Histological Response Assessment (Cases)	Biochemistry													Immunohistochemistry†
			Residual Cellularity Assessment (Frozen Samples)‡	WB Beclin1	WB PI3KIII	WB Bcl2	WB LC3B-II	Co-IP Experiments			WB Caspase 3		WB Caspase 7	WB Lamin A		Beclin1	PI3KIII	Bcl2	Caspase 3	Lamin A
								IP Beclin1/WB Beclin1	IP Beclin1/WB PI3KIII	IP Beclin1/WB Bcl2	Full Length	Cleaved	Cleaved	Full Length	Cleaved				Cleaved	Full Length	Cleaved
Treated patients§
1	r	High	b	1+	+w	+w	-	1+	ne	-	+w	-	-	1+	-	+	+w	+w	-	+	-
2	r	High	b	1+	+w	+w	-	1+	+w	-	1+	-	-	1+	-	+	+	+	-	+	-
3	r	High	b	1+	+w	+w	+w	1+	1+	-	1+	-	-	1+	-	+	+w	+w	-	+	-
4	r	Moderate	c	2+	1+	1+	+w	2+	1+	+w	1+	-	-	1+	-	+	+	+	-	+	-
5	r	Moderate	c	2+	1+	1+	1+	2+	1+	+w	1+	-	-	1+	-	+	+	+w	-	+	-
6	r	Moderate	c	2+	+w	+w	+w	2+	1+	+w	1+	-	-	1+	-	+	+	+w	-	+	-
7	r	Low	a	1+	-	-	-	1+	-	-	1+	-	-	1+	-	+	+	+	-	+	-
8	r	Low	d	2+	2+	1+	2+	2+	2+	1+	1+	-	-	1+	-	+	+	+w	-	+	-
9	r	Low	d	2+	2+	2+	2+	2+	1+	1+	1+	-	-	1+	-	+	+	+	-	+	-
10	p	Low	d	2+	2+	2+	2+	2+	1+	+w	1+	-	-	1+	-	+	+	+	-	+	-
11	p	Low	d	2+	1+	1+	+w	2+	1+	+w	1+	-	-	1+	-	+	+	+	-	+	-
Untreated patients
1		/	2+	2+	1+	2+	2+	1+	+w	1+	-	-	1+	-	+	+	+	-	+	-
2		/	2+	2+	2+	2+	2+	2+	1+	1+	-	-	1+	-	+	+	++	-	+	-

+w indicates weak positive; Co-IP, coimmunoprecipitation; IP, immunoprecipitation; ne, not evaluable.

^*p indicates progression; r, response.

^†Immunohistochemistry of paraffin-embedded sections of samples showing comparable residual cellularity to that of the corresponding frozen samples.

^‡a <10%, b 10% to 50%, c 50% to 90%, d >90%.

^§The numbers in bold are patients who participated in a study of advanced GIST (three of which, nos. 4, 6, and 7, were described in a previous article [3] as 14, 19, and 25, respectively); the numbers in italics are those treated using the neoadjuvant protocol.